• Subjects aged ≥ 18 years.

• Cohort A (Neuroendocrine Tumor) Only:

⁃ --Subjects with well differentiated neuroendocrine tumors who are either on a watch- and-wait approach or receiving treatment with somatostatin analog(s). Patient who received and completed another active treatment but are on a break from treatment will be allowed to enroll (e.g., patients that had completed PRRT).

• Cohort B (Gynecological Cancer) Only:

⁃ --Subjects with early-stage (I or II) ovarian/fallopian-tube cancer in surveillance who have completed all treatment or are receiving adjuvant treatment with platinum-based chemotherapy +/- maintenance therapy with PARP inhibitor(s) or bevacizumab.

• Or

⁃ --Subjects with endometrial cancer which is low risk, low-intermediate risk in surveillance, or high-intermediate risk receiving brachytherapy. Risk category is based on GOG criteria.

• ECOG Performance Status ≤ 2.

• Documentation of a score of 4 or higher when answering either of the NCCN-recommended screening questions (How exhausted do you feel on a scale of 0 to 10? or How impaired do you feel by this fatigue on a scale of 0 to 10?) within 4 weeks prior to randomization

• Adequate organ function as defined as:

‣ Hematologic:

• Hemoglobin ≥ 9 g/dL

⁃ Hepatic:

• Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)

∙ AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN ----Subjects with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.

⁃ Renal:

∙ --Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula

⁃ For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

• Women \< 50 years of age:

⁃ ---Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or

⁃ ---Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).

∙ Women ≥ 50 years of age:

‣ Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments and luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or Amenorrhea for 24 months following cessation of all exogenous hormonal treatments, if applicable; or

⁃ Had radiation-induced menopause with last menses \>1 year ago; or

⁃ Had chemotherapy-induced menopause with last menses \>1 year ago; or

⁃ Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).

⁃ Female subjects of childbearing potential and male subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception.

⁃ Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.